10-Q/A: Phathom Pharmaceuticals Files Amended 10-Q Report, Citing Inadvertent Omission in Certifications

Phathom Pharmaceuticals has filed an amended 10-Q report to correct an inadvertent omission of language in the certifications of its CEO and CFO.

Summary

• Phathom Pharmaceuticals filed an amendment to its original quarterly report on Form 10-Q for the period ended March 31, 2024, to include revised certifications from the CEO and CFO.
• The amendment was necessary because the original certifications inadvertently omitted language from paragraph 4(b).
• The company's cash and cash equivalents decreased from $381.4 million at the end of 2023 to $322.2 million as of March 31, 2024.
• Net product revenue for the quarter was $1.9 million, with a gross profit of $1.5 million.
• The company reported a net loss of $82.9 million, or $1.42 per share, for the quarter ended March 31, 2024, compared to a net loss of $37.8 million, or $0.89 per share, for the same period in 2023.
• Total operating expenses were $71.4 million for the quarter, including $62 million in selling, general, and administrative expenses.
• The company has a revenue interest financing liability of $302.5 million and long-term debt of $149 million.
• The company has a minimum purchase obligation of approximately $2.8 million with Sandoz.
• The company has operating leases for office space with weighted average remaining lease terms of 1.1 and 1.4 years.
• The company has a loan agreement with Hercules Capital with a total potential borrowing of $300 million, of which $158.9 million was outstanding as of March 31, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has launched its products and generated some revenue, the significant net loss, high operating expenses, and cash burn are concerning. The company's reliance on debt and revenue interest financing also adds risk. The need for additional funding is a potential negative.

Positives

• The company generated $1.9 million in net product revenue in the first quarter of 2024, indicating initial commercial sales of its products.
• The company has access to a significant amount of capital through its loan agreement with Hercules Capital, with a total potential borrowing of $300 million.
• The company has a revenue interest financing agreement that provides additional funding.

Negatives

• The company experienced a significant net loss of $82.9 million for the quarter ended March 31, 2024, which is more than double the loss from the same period last year.
• The company's cash and cash equivalents decreased by approximately $59 million during the quarter.
• Selling, general, and administrative expenses were very high at $62 million for the quarter.
• The company has a substantial revenue interest financing liability of $302.5 million.
• The company has a significant amount of long-term debt at $149 million, net of discount.

Risks

• The company has a history of net losses and negative cash flows from operating activities and expects to continue to incur additional net losses in the future.
• The company's sales and income potential is unproven.
• The company's ability to continue as a going concern is dependent on its ability to acquire additional funding.
• The company's estimates for variable consideration in revenue recognition may differ from actual results.
• The company's revenue interest financing liability is subject to changes based on future sales and default events.
• The company's loan agreement with Hercules Capital includes financial covenants that must be met.

Future Outlook

Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these financial statements were issued, but there is no assurance that the company will be successful in acquiring additional funding if needed.

Management Comments

• Management is required to perform a two-step analysis over the Company's ability to continue as a going concern.
• Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these financial statements were issued.

Industry Context

The company is operating in the biopharmaceutical industry, which is characterized by high research and development costs, long development timelines, and regulatory hurdles. The company's focus on gastrointestinal diseases is a specific niche within this industry. The commercial launch of VOQUEZNA products is a key milestone for the company, and its success will be critical for its future financial performance.

Comparison to Industry Standards

• Phathom's high operating expenses, particularly in selling, general, and administrative costs, are not uncommon for a company in the early stages of commercialization in the pharmaceutical industry. Companies like Amarin Corporation (AMRN) and Esperion Therapeutics (ESPR) have also experienced high SG&A expenses during their launch phases.
• The company's reliance on debt and revenue interest financing is a common strategy for biotech companies that are not yet profitable. However, the high level of debt and the revenue interest financing liability could pose a risk if sales do not meet expectations. Companies like Biohaven Pharmaceutical (BHVN) have also used similar financing strategies.
• The company's net loss of $82.9 million for the quarter is significant, but not unusual for a biotech company in the commercialization phase. Many companies in this sector, such as Cassava Sciences (SAVA) and Amylyx Pharmaceuticals (AMLX), have reported substantial losses while they are building their commercial infrastructure and sales.
• The company's cash burn rate is a concern, as its cash and cash equivalents decreased by approximately $59 million during the quarter. This is a common challenge for biotech companies, and they often need to raise additional capital to fund their operations. Companies like Sage Therapeutics (SAGE) have also faced similar cash burn challenges.
• The company's revenue of $1.9 million is a positive sign, but it is still relatively low compared to the operating expenses. It will be important to monitor the company's sales growth in the coming quarters to assess its commercial potential. Companies like Acadia Pharmaceuticals (ACAD) have demonstrated the potential for rapid sales growth after a successful product launch.

Related Party Transactions

• Frazier Life Sciences IX, L.P., a principal stockholder, is compensated for their participation on the Board of Directors.
• The company incurred expenses related to services performed by PCI Pharma Services, a company in which Frazier is also a principal stockholder.
• The company has a temporary services agreement with Takeda Pharmaceutical Company Limited, a common stockholder.

Stakeholder Impact

• Shareholders are impacted by the company's net losses and the decrease in cash and cash equivalents.
• Employees are impacted by the company's financial performance and its ability to continue operations.
• Customers are impacted by the availability of the company's products.
• Suppliers are impacted by the company's ability to pay for goods and services.
• Creditors are impacted by the company's debt obligations and its ability to repay them.

Next Steps

• The company needs to focus on increasing sales of its VOQUEZNA products to improve its financial performance.
• The company needs to manage its operating expenses to reduce its net losses.
• The company needs to monitor its cash burn rate and secure additional funding if necessary.
• The company needs to comply with the financial covenants under its loan agreement with Hercules Capital.

Key Dates

Keywords

Phathom Pharmaceuticals, 10-Q, Amendment, Financial Results, Revenue, Net Loss, Operating Expenses, Debt, Loan Agreement, Revenue Interest Financing, VOQUEZNA, Commercial Launch, FDA Approval